News & Events

• Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660
  Published on 2020-02-04
• Seres Therapeutics Appoints Stephen Berenson as Chairman of its Board of Directors
  Published on 2019-12-16
• Vedanta Biosciences Announces Initiation of First-in-Patient Study of Immuno-Oncology Candidate VE800 In Combination with Bristol-Myers Squibb’s Opdivo® (Nivolumab)
  Published on 2019-12-05
• Vedanta Biosciences Awarded $5.8 Million CARB-X Grant to Accelerate Development of VE707 for Multi-Drug Resistant Infections
  Published on 2019-12-05
• Seres Therapeutics to Present at the Stifel 2019 Healthcare Conference
  Published on 2019-11-14
• Vedanta Biosciences’ Silvia Caballero, Ph.D., Named to TIME 100 NEXT List for Innovative Leaders
  Published on 2019-11-13
• Seres Therapeutics Reports Third Quarter Financial Results and Provides Business Update
  Published on 2019-11-05
• Seres Therapeutics to Host Third Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on November 5, 2019
  Published on 2019-10-31
• Vedanta Biosciences CEO Receives 2019 Immigrant Entrepreneur Award
  Published on 2019-10-30
• Interview with Jim Weston and Stephen Conafay of MTIG
  Published on 2019-10-01
• Microbiome Therapeutics Innovation Group Highlights Member Company Activity at IDWeek 2019
  Published on 2019-10-01
• Vedanta Biosciences Announces $16.6 Million Series C-2 Financing
  Published on 2019-09-23
• Rebiotix, Inc. and Karolinska Institutet Expand Partnership to Shape the Future of Microbiome Research
  Published on 2019-09-03
• LUCA Biologics Launches to Develop Live Biotherapeutics for Women’s Health Starting with Urinary Tract Infection (UTI)
  Published on 2019-08-07
• Seres Therapeutics Reports Second Quarter Financial Results and Provides Progress Update
  Published on 2019-08-06